NCI-designated Consortium Cancer Center
|
|
|
WEEKLY RESEARCH NEWSLETTER
|
|
|
The UC San Diego Office of the Vice Chancellor for Health Sciences is delighted to host a series of guest lectures as part of the Moores Cancer Center Director recruitment effort. Each lecturer will highlight his or her personal achievements in education, research, and/or clinical care and provide a brief vision for the Moores Cancer Center.
|
|
|
|
Robert Winn, M.D.
Director and Lipman Chair of Oncology
VCU Massey Cancer Center
June 27, 2022
5:00 p.m. - 6:00 p.m.
ACTRI Auditorium
In-person capacity limited to 60
The seminar also will be available via Zoom
ZOOM MEETING LINK
|
|
|
NOW ACCEPTING APPLICATIONSFOR VICE CHAIR DSMC
|
|
|
Compensation
Effort: 5% up to NIH cap
Required Qualifications
Faculty Member of UCSD, SDSU, or LJI with experience as a PI of a cancer clinical trial
Moores Cancer Center Member
Experience as PI/Site PI of Phase 1/Phase 2 Investigator Initiated Trials
Preferred Qualifications
An ideal candidate would have experience in both industry sponsored and investigator-initiated cancer therapeutics trials.
Detail oriented
Committed to maintaining the integrity of clinical trials at Moores Cancer Center and executing the Data Safety and Monitoring Plan as written in the Cancer Center Support Grant (CCSG)
Time Commitment: 2-4 hours per month for Committee meetings, plus time to review material prior to meetings, more depending on level of involvement with other projects or potential of ad hoc reviews.
Term
The recommended terms is 3 years.
MORE INFO
|
| |
|
Moores Cancer Center
Senior Leadership Change
|
|
|
Jing Yang, Ph.D.
Professor, Departments of Pharmacology and Pediatrics, UC San Diego, School of Medicine
Co-Leader, Cancer Biology and Signaling Program, UC San Diego, Moores Cancer Center
|
|
Dong-Er Zhang, Ph.D.
Distinguished Professor and Vice Chair of Molecular Biology, UC San Diego, School of Biological Sciences
|
|
|
Please join us in welcoming Jing Yang, Ph.D, Professor of Pharmacology and Pediatrics, as the new Cancer Biology and Signaling Program Co-Leader, joining current Co-Leader, Kun-Liang Guan, Ph.D., Distinguished Professor of Pharmacology at UC San Diego.
Dr. Yang’s research elucidates the molecular basis of tumor metastasis and identifies new targets for anti-metastasis therapy. Her ground-breaking research not only demonstrates a critical role of the Epithelial-Mesenchymal Transition (EMT) program in tumor metastasis, but also brought EMT to the forefront of cancer research. Her lab continues to use (1) functional genomics and cellular and molecular biology approaches in 3D organoid cultures and (2) mouse tumor models to uncover novel genes and signaling pathways regulating EMT and tumor metastasis. Dr. Yang has received a number of awards for her work, such as the NIH Director’s New Innovators Award, the American Cancer Society Scholar award, and the John J. Abel Award from ASPET.
Dr. Yang has served several leadership roles in biomedical research and training, such as Vice President and then President of the EMT International Association from 2013 to 2019 and Member of the 2020 AACR Annual Meeting Education Session Organization Committee. In addition, she is the PI and Co-Eirector of the UCSD NCI T32 Cancer Training program "Contemporary Approaches on Cancer Cell Signaling and Communication."
Dr. Yang is stepping into the role held since 2008 by Dong-Er Zhang, Ph.D., Distinguished Professor and Vice Chair of Molecular Biology at UC San Diego. Dr. Zhang will continue her scientific leadership through teaching and research. Dr. Zhang is an outstanding scientist in the research areas of molecular mechanisms of normal hematopoiesis and the development of related diseases. She has served as the principal investigator for numerous NIH, DoD, and ACS research grants and as the designated mentor/sponsor on fellowships from the NIH and private foundations. In this process, over 40 trainees have graduated from her lab, and many of them have become leaders in academia or industry. Dr. Zhang has served as a member of the Board of Scientific Counselors of Basic Sciences of NCI and is a current member of the American Association for the Advancement of Science, American Society of Hematology and the American Society of Biochemistry and Molecular Biology (ASBMB). Dr. Zhang has provided outstanding partnership to Dr. Guan and exceptional leadership for the Cancer Biology and Signaling Program at Moores Cancer Center. We thank her for her dedicated service and welcome her ongoing research collaboration.
Join us in not only welcoming Dr. Jing Yang to her new role in Moores Cancer Center leadership as a strong, new partner to Dr. Kun-Liang Guan, but also expressing an immense thank you to Dr. Dong-Er Zhang for her service to the research of Cancer Biology and Signaling for San Diego’s only NCI-designated comprehensive cancer center.
|
|
|
|
Vineet Bafna, Ph.D., Professor, UC San Diego, Jacobs School of Engineering, Department of Computer Science and Engineering and Member, UC San Diego, Moores Cancer Center, Structural and Functional Genomics Program, is one of the co-Is on the eDyNAmiC team that was just awarded $25M from the Cancer Grand Challenges Summit.
|
|
| Mark Foundation Endeavor Informational Session
|
|
|
The Foundation and Research Relations team is delighted to offer you an opportunity to learn more about an exciting research program from the Mark Foundation for Cancer Research called Endeavor.
This new program is designed to promote interdisciplinary science that brings together investigators with diverse areas of expertise to solve large-scale problems in the prevention, diagnosis, and treatment of cancer.
This grant program awards teams of three or more investigators up to $1M/year for up to 3 years to generate and integrate data from diverse lines of research and transform those insights into advances for cancer patients that could not be achieved by individual efforts.
On Thursday, June 23, from 12:00 p.m. to 1:00 p.m., we are partnering with the Foundation and Research Relations Team to host an informational session that provides an opportunity to learn more about this program, which will include application guidelines, competitive insights, timeline, and other helpful tips for anyone interested in applying. To RSVP, please use this link to the RSVP SmartSheet.
Thank you, and we hope to see you in the virtual informational session for this exciting opportunity for interdisciplinary team science!
Questions? Contact John Matthews in UC San Diego, Foundation and Research Relations.
|
|
|
Gabrielle’s Angel Foundation
Two Limited Submission Grant opportunities for Junior Faculty
|
|
|
Deadline: Internal LOI Submission Deadline: Monday, June 27, 2022
Questions: Please contact Angela Ballantyne, Ph.D.
Gabrielle’s Angel Foundation has two Limited Submission grant opportunities for junior faculty. Institutions may submit only one application per grant type (see attached Grant Guidelines). If you are interested in being the MCC nominee for one of the below grant types, please submit a 1-page INTERNAL LOI to MCC by Monday, June 27, 2022 (instructions below).
Description: Gabrielle’s Angel Foundation for Cancer Research is interested in funding innovative and insightful medical research on hematologic malignancies (e.g., novel and state-of-the-art techniques to address fundamental problems in the genesis and treatment of blood-related cancers). Projects will be funded for a three-year period at $75,000.00 per year. The two grant types are:
- Conventional / Mainstream Research
- Integrative / Complementary Research
(If you are chosen to proceed with a full application to Gabrielle’s Angel Foundation, their deadline for full proposals is August 26, 2022.)
If you are interested in applying for one of the above grants (Conventional or Integrative), please submit a 1-page INTERNAL LOI to MCC by the deadline of Monday, 6/27/2022 at 5 p.m. for review by our grants committee. Your LOI must be submitted to Angela Ballantyne, Ph.D. in a single pdf (includes 1 thru 3 below):
- Cover page: Include your name, degree(s), complete academic title, department, phone number, and email address
- Gabrielle’s Angel grant type
- Statement of your eligibility per Gabrielle’s Angel guidelines
- Project title
Research Statement (1-page maximum):
- Arial, 11-point font, at least 1/2 inch margins all around
- 1-page maximum, including any Figures, Tables, etc.
- Citations only may be included on a second page
Briefly describe the nature of the research project, including a brief summary of aims, significance and rationale, preliminary data, and the research plan.
NIH-style biosketch
5 pages max; include active and pending support
Your LOI submission is NOT complete until you have received Acknowledgment of Receipt.
|
|
|
Nominate an Emerging Leader in IO
|
|
|
|
SITC is pleased to announce the call for nominations for the 2022 Steven A. Rosenberg Scholars Award, one of the society's most prestigious opportunities for early career scientists.
The society is seeking the best and brightest to continue Dr. Rosenberg’s legacy with a research award for early career scientists who are interested in tackling the challenges that face the field of cancer immunotherapy. Nominations are due July 15, 2022 and will be accepted via email to development@sitcancer.org.
|
|
|
CCSG Structural and Functional Genomics Cross Laboratory Meeting
Thursday, June 22, 2022
12:00 p.m. - 1:00 p.m.
Shailja C. Shah, M.D., M.P.H.
UC San Diego, School of Medicine, Division of Gastroenterology
Staff Physician, GI Section, VA San Diego Healthcare System
|
|
| Highlighted Funding Opportunities
|
|
|
DoD Breast Cancer Research Program: Transformative Breast Cancer Consortium Award
$25M direct for up to 4 years
The U.S. Department of Defense, Transformative Breast Cancer Consortium Award is designed to support collaborations and ideas that will transform the lives of individuals with, and/or at risk for, breast cancer and accelerate progress toward ending breast cancer. Applicants must bring together different perspectives to develop new paradigms that will solve fundamental yet overarching problems in breast cancer.
Pre-Application Deadline: August 8, 2022
MORE INFO
|
|
|
NCCN Request for Proposals (RFP)
National Comprehensive Cancer Network® (NCCN®) is pleased to announce a collaboration with AstraZeneca Pharmaceuticals (AstraZeneca) to offer a new funding opportunity for NCCN Member Institution faculty. This opportunity is seeking Letters of Intent (LOIs), and ultimately proposals, to improve the quality of care, including the delivery of guideline concordant care, and additional innovations in the care delivery for patients with limited and extensive stage Small Cell Lung Cancer (LS-SCLC and ES-SCLC). Please note that this document can also be accessed online here.
RFP: NCCN and AstraZeneca Quality Improvement Initiative: Improving the Quality of Care and Application of Best Practices in the Treatment of Patients with Small Cell Lung Cancer (SCLC) Research Grant Opportunity
LETTER of INTENT Due By: Monday, June 27, 2022, by 5:00 p.m. ET
Open to: NCCN Member Institution Faculty
Please direct questions regarding this RFP to Nicole Zion at zion@nccn.org with the subject line, “2022 NCCN AZ SCLC RFP.”
|
|
|
Other Funding Opportunities
|
|
|
CA22-015 Cancer Control Research in Persistent Poverty Areas (U54 Clinical Trial Optional)
Award: $1.5M direct/year for up to 5 years
To provide resources to support the time and effort of transdisciplinary teams, in collaboration with institutions, clinics, and communities/tribes, to develop a cancer prevention and control research program and provide support to early-career investigators that targets and serves populations living in persistent poverty areas.
Deadline: July 6, 2022
MORE INFO
|
Tobacco Centers of Regulatory Science (TCORS) for Research Relevant to the Family Smoking Prevention and Tobacco Control Act (U54)
Award: Via support from the FDA Center for Tobacco Products (CTP), intends to fund eight TCORS, corresponding to a total of $32 million, for fiscal year 2023
Future year amounts will depend on the availability of funds.
Deadline: July 14, 2022
MORE INFO
|
CA22-017 Small Business Transition Grant For Early Career Scientists (R42 Clinical Trial Not Allowed)
Award: Total $275,766 for Phase I awards; $1,838,436 for Phase II awards (NCI 2 years each)
To support not only early-career academic scientists interested in transitioning to entrepreneurship, but also the transfer of technology from academic laboratories to small businesses.
Deadline: August 22, 2022
MORE INFO
|
Administrative Supplements to Support Cancer Disparity Collaborative Research
Award: $150,000 direct for 1 year
The purpose of this trans-NCI Funding Opportunity Announcement (FOA) is (1) to promote new cancer disparities research among investigators who do not normally conduct it and (2) to encourage the partnership of experienced cancer research investigators with cancer disparities-focused researchers. Cancer disparities research includes, but is not limited to basic, translational, behavioral, observational, interventional, environmental, and population research studies that address the adverse differences in cancer incidence, prevalence, mortality, survivorship, burden, and/or response to treatment in racial/ethnic minorities and/or underserved population groups.
Deadline: September 6, 2022
|
MD22-008 Understanding and Addressing Misinformation among Populations that Experience Health Disparities (R01 - Clinical Trials Optional)
Award: $500K direct/year for up to 5 years
To support research that seeks to (1) understand the underlying mechanisms and (2) test interventions to address and mitigate the impact of health-related misinformation and disinformation on health disparities and the populations that experience health disparities.
Deadline: November 13, 2022
MORE INFO
|
Early-Stage/Advanced/Sustained Development of Informatics Technologies for Cancer Research and Management (R21/U01/U24 Clinical Trial Optional
Award: $275K unlimited direct costs 2-5 years, depending on mechanism
This component of the NCI's Informatics Technology for Cancer Research (ITCR) Program; targets the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum.
Deadline: November 17, 2022
|
|
|
DoD Breast Cancer Research Program (BCRP): Anticipated Funding Opportunities
These U.S. Department of Defense BCRP awards will support innovative, high-impact research, with a mission of ending breast cancer for service members, veterans, and the general public. Funding mechanisms will include Breakthrough Awards, Era of Hope Scholar Awards, and Innovator Awards.
MORE INFO
|
|
|
FOUNDATION FUNDING OPPORTUNITIES
|
|
|
Hartwell Individual Biomedical Research Award
$300,000 for 3 years
Proposed projects must address a specific and compelling unmet need to improve health outcomes for children by either clinical translation of theory or application or the strategic solution of a complex technical problem with the potential to advance translational biomedical research. The foundation seeks to fund early-stage research that is strategic or translational in nature. Preliminary data are not required. In all cases, the foundation seeks not only risk-taking innovation that addresses an unmet need and has the potential for clinical translation if successful, but also proposed projects that accept uncertainty and leverage technology--not merely study it.
UC San Diego may nominate three applicants.
Internal Submission Deadline: June 28, 2022 at 5:00 p.m.
Funding Organization's Deadline: September 15, 2022
MORE INFO
|
|
|
The Innovation Award
Specifically designed to provide funding to extraordinary early career researchers who have an innovative new idea but lack sufficient preliminary data to obtain traditional funding. It is not designed to fund incremental advances. The research supported by the award must be novel, exceptionally creative and, if successful, have the strong potential for high impact in the cancer field.
Deadline: July 6, 2022
MORE INFO
|
|
|
Mark Foundation for Cancer Research: Endeavor Collaborative Research Awards
$3,000,000 over 3 years
The Mark Foundation Endeavor Awards support collaborative research projects that bring together investigators with diverse areas of expertise to tackle challenges in the prevention, diagnosis, and treatment of cancer. These grants are awarded to teams of three or more investigators to generate and integrate data from diverse lines of research and transform those insights into advances for cancer patients that could not be achieved by individual efforts. A description of the teams granted Endeavor Awards in 2022 can be found here.
MORE INFO
*See Mark Foundation Endeavor Informational Session announcement under News & Announcements above for more information about this opportunity.
|
|
|
MCC’s Cancer Health Equity Collaborative (CHEC) Meeting
Thursday, June 23, 2022
10:00 a.m. - 12:00 p.m.
-
Presentations from the California LGBTQ Health and Human Services Network on inclusive access to cancer care, Pfizer Oncology on diversity in clinical trials, as well as community partner updates.
If you are interested in attending, please contact Valesca Largaespada.
|
|
|
|
Tuesday, October 11, 2022
UC San Diego, Moores Cancer Center
Delivering Discoveries Annual Scientific Retreat
Location: Scripps Seaside Forum
8610 Kennel Way, La Jolla, CA 92037
|
|
|
Thursday - Friday, October 20-21, 2022
Time: TBD
Sanford Stem Cell Annual Symposium co-hosted by Moores Cancer Center, Hematologic Malignancies Program
Location: Sanford Consortium, Duane J. Roth Auditorium
2880 Torrey Pines Scenic Drive, La Jolla, CA 92037
- Recent breakthroughs in regenerative medicine
-
Stem cell regeneration in several disease areas
- Interactive discussion panels regarding stem cells in space and stem cell clinical trials
Hosted by
Catriona Jamieson, M.D., Ph.D., Deputy Director of Moores Cancer Center, Director of the Sanford Stem Cell Clinical Center, and Chief of the Division of Regenerative Medicine and Alysson Muotri, Ph.D., Co-Director, Stem Cell Program
Keynote Speakers
Derrick Rossi, Ph.D., Co-Founder, Moderna; Elizabeth Blackburn, Ph.D., Professor, UC San Francisco; and Thomas C. Sudhof, M.D., Professor, Stanford University
MORE INFO
|
Tuesday - Saturday, November 8-12, 2022
Join Us in Person at SITC 2022
37th Annual Meeting & Pre-Conference Programs
Location: Boston Convention and Exhibition Center, Boston, MA. Virtual participation also available at the same registration rates.
REGISTER TODAY!
|
Saturday, January 28, 2023
Prostate Cancer Patient Summit
|
|
|
| Sandip Patel, M.D., Named Researcher of the Month
VIDEO LINK
|
|
| Newly opened clinical trials (June, 2022)
|
|
|
| Now Accepting Applications for
Vice Chair of DSMC
|
|
|
- Research Grant Writer and Editor for the Gleiberman Head & Neck Cancer Center - #116068
-
[MULTIPLE POSTINGS] Pre-Award Fund Manager RA3 (remote or hybrid) - #116028
-
[MULTIPLE POSTINGS] Post-Award Fund Manager RA3 (remote or hybrid)- #115272
|
|
|
If you have newsworthy items to contribute, then please contact our Marketing & Communications Manager, Renee Maude at amaude@health.ucsd.edu.
|
|
|
Moores Cancer Center is not only one of only 52 NCI-designated comprehensive cancer centers in the nation, but also the only one providing multidisciplinary, research-driven detection, treatment, survivorship, and prevention in the San Diego County region. The 360 member scientists and clinicians come from 22 UC San Diego specialty departments, Rady Children’s Hospital, San Diego State University, and the La Jolla Institute of Immunology.
With strengths in stem cell research, immune-oncology, precision medicine, cancer disparities, and pre-cancer and risk research, our researchers address translational oncology and drug development through partnerships with biotechnology and pharmaceutical companies. The Moores Cancer Center was founded in 1978, the same year it received its NCI designation.
|
Research Administration Department
|
|
|
Manage your preferences | Opt Out using TrueRemove™
Got this as a forward? Sign up to receive our future emails.
View this email online.
|
3855 Health Sciences Drive MC 0698 | La Jolla, CA 92093 US
|
|
|
This email was sent to .
To continue receiving our emails, add us to your address book.
|
|
|
|
